Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Biallelic NFATC1 mutations cause an inborn error of immunity with impaired CD8 + T-cell function and perturbed glycolysis

Blood (2023) 142 (9): 827–845.

https://doi.org/10.1182/blood.2022018303

Published: 2023

Includes: Supplemental data

Journal Articles

Overexpression of PD-L1 Correlates with JAK2 -V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-137447

Published: 2020

Journal Articles

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms

Blood (2019) 134 (2): 199–210.

https://doi.org/10.1182/blood.2019000519

Published: 2019

Includes: Supplemental data

Journal Articles

Mutational Landscape of the Transcriptome Offers a Rich Neoantigen Resource for Immunotherapy of Myeloproliferative Neoplasms

Blood (2018) 132 (Supplement 1): 3058.

https://doi.org/10.1182/blood-2018-99-118049

Published: 2018

Journal Articles

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms

Blood (2016) 127 (3): 325–332.

https://doi.org/10.1182/blood-2015-07-661835

Published: 2016

Includes: Supplemental data

Journal Articles

Whole Exome Sequencing Identifies Novel MPL and JAK2 M utations in Triple Negative Myeloproliferative Neoplasms

Jelena D Milosevic Feenstra, PhD, Harini Nivarthi, PhD, Heinz Gisslinger, MD, Emilie Leroy, Elisa Rumi, MD, Ilyas Chachoua, Klaudia Bagienski, Blanka Kubesova, MSc, Daniela Pietra, PhD, Bettina Gisslinger, Roland Jäger, PhD, Doris Chen, PhD, Tiina Berg, B.Sc., Martin Schalling, MSc, Michael Schuster, PhD, Christoph Bock, PhD, Stefan N. Constantinescu, MD PhD, Mario Cazzola, MD, Robert Kralovics, PhD

Blood (2015) 126 (23): 606.

https://doi.org/10.1182/blood.V126.23.606.606

Published: 2015

Journal Articles

Ultimate Outcomes of Patients with Recurrent Diffuse Large B Cell Lymphoma Who Do Not Respond to Second-Line Chemotherapy

Rebecca Elstrom, MD, Peter Martin, Katya Ostrow, Jacqueline Barrientos, Richard R. Furman, Jia Ruan, Michael Schuster, Tsiporah Shore, Amy Chadburn, Morton Coleman, MD, John P. Leonard, MD

Blood (2008) 112 (11): 4940.

https://doi.org/10.1182/blood.V112.11.4940.4940

Published: 2008

Journal Articles

Cyclophosphamide Overcomes the Suppressive Effect of LenalidomideTherapy on Stem Cell Collection in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.

Tomer Mark, MD, David Jayabalan, Roger N. Pearse, MD/PhD, Jessica Stern, Jessica Furst, April Rambo, RN, John Harpel, MD/PhD, Tsiporah Shore, MD, Michael Schuster, MD, John P. Leonard, MD, Paul J. Christos, MPH, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2007) 110 (11): 3024.

https://doi.org/10.1182/blood.V110.11.3024.3024

Published: 2007

Journal Articles

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

Blood (2007) 110 (10): 3557–3560.

https://doi.org/10.1182/blood-2006-08-036947

Published: 2007

Includes: Supplemental data

Journal Articles

Utility of Bortezomib Retreatment for Patients with Relapsed Multiple Myeloma.

Jeffrey Lee Wolf, MD, Paul Richardson, MD, Michael Schuster, MD, Annette LeBlanc, David Battleman, MD, MSc, Ian Walters, MD

Blood (2006) 108 (11): 3532.

https://doi.org/10.1182/blood.V108.11.3532.3532

Published: 2006

Journal Articles

Phase II Trial of Prochymal™ (Ex-Vivo Cultured Adult Human Mesenchymal Stem Cells) and Corticosteroids as Primary Treatment for Acute Graft-Vs-Host Disease (aGVHD).

Partow Kebriaei, MD, Luis Isola, MD, Erkut Bahceci, MD, H. Kent Holland, MD, Scott Rowley, MD, Joseph McGuirk, DO, Marcel Devetten, MD, Jan Jansen, MD, PhD, Roger Herzig, MD, Michael Schuster, MD, Joseph Uberti, MD, PhD

Blood (2006) 108 (11): 3231.

https://doi.org/10.1182/blood.V108.11.3231.3231

Published: 2006

Journal Articles

Breaking the Plateau Response in Myeloma: Preliminary Results of a Phase II Pilot Study of Sequential Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) in Patients No Longer Responsive to Standard Induction Regimens.

Brian A. Di Carlo, MD, Jessica L. Stern, Michael Schuster, MD, Tsiporah Shore, MD, John Harpel, MD, PhD, Roger Pearse, MD, PhD, Faiza Zafar, PA, Joanne Dymek, NP, Jessy Ryan, NP, David Jayabalan, MA, Selina Chen-Kiang, PhD, Scott Ely, MD, John P. Leonard, MD, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2006) 108 (11): 3538.

https://doi.org/10.1182/blood.V108.11.3538.3538

Published: 2006

Journal Articles

A Phase II Study of PXD101 in Advanced Multiple Myeloma.

Daniel Sullivan, MD, Seema Singhal, MD, Michael Schuster, MD, James Berenson, MD, Peter Gimsing, MD, Finn Wislöff, MD, Anders Waage, MD, Melissa Alsina, MD, Robert Gerwien, PhD, Anne Clarke, RN, MPH, Karen Moller, Chean Eng Ooi, PhD

Blood (2006) 108 (11): 3583.

https://doi.org/10.1182/blood.V108.11.3583.3583

Published: 2006

Journal Articles

FDG-PET May Be Helpful in the Determination of Transformation to an Aggressive Subtype in Low-Grade Lymphoma.

Lale Kostakoglu, MD, Stanley J. Goldsmith, MD, Amy Chadburn, MD, Erez Vidan, MD, Michael Schuster, MD, Paul Christos, M.S., MPH, Morton Coleman, MD

Blood (2005) 106 (11): 1927.

https://doi.org/10.1182/blood.V106.11.1927.1927

Published: 2005

NARROW

Biallelic NFATC1 mutations cause an inborn error of immunity with impaired CD8 + T-cell function and perturbed glycolysis

Overexpression of PD-L1 Correlates with JAK2 -V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms

Mutational Landscape of the Transcriptome Offers a Rich Neoantigen Resource for Immunotherapy of Myeloproliferative Neoplasms

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms

Whole Exome Sequencing Identifies Novel MPL and JAK2 M utations in Triple Negative Myeloproliferative Neoplasms

Ultimate Outcomes of Patients with Recurrent Diffuse Large B Cell Lymphoma Who Do Not Respond to Second-Line Chemotherapy

Cyclophosphamide Overcomes the Suppressive Effect of LenalidomideTherapy on Stem Cell Collection in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

Utility of Bortezomib Retreatment for Patients with Relapsed Multiple Myeloma.

Phase II Trial of Prochymal™ (Ex-Vivo Cultured Adult Human Mesenchymal Stem Cells) and Corticosteroids as Primary Treatment for Acute Graft-Vs-Host Disease (aGVHD).

Breaking the Plateau Response in Myeloma: Preliminary Results of a Phase II Pilot Study of Sequential Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) in Patients No Longer Responsive to Standard Induction Regimens.

A Phase II Study of PXD101 in Advanced Multiple Myeloma.

FDG-PET May Be Helpful in the Determination of Transformation to an Aggressive Subtype in Low-Grade Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only